NASDAQ · Medical Devices · USD
Lifeward Ltd. (LFWD) Stock Analysis
Lifeward Ltd. (LFWD) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
LFWD Key Statistics
As of Oct 21, 2026Trading
- Open
- $5.52
- Previous Close
- $5.61
- Day's Range
- 5.45–5.61
- 52-Week Range
- 4.14–9.61
- Volume
- 4.13K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.48
Valuation
- Market Cap
- $15.58M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 0.71
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −15.73
Financials (FY)
- Revenue (FY)
- $22.03M−14.14%
- Net Income (FY)
- −$19.91M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −141.28%
- Shares Outstanding
- 2.83M
- 1-Year Return
- −32.60%
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 5.58K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, LFWD closed at $5.50, −32.60% over 1 year.
Lifeward Ltd. (LFWD) has a market capitalization of $15.58M.
In fiscal 2025, LFWD reported revenue of $22.03M.
LFWD Stock Return by Calendar Year
Lifeward Ltd. (LFWD) 10-year return: what $10,000 became
- 1 year
- $10,000 $6,740
- −32.60%
- 5 years
- $10,000 $481
- −95.19%
- 10 years
- $10,000 $5
- −99.95%
If you had invested $10,000 in Lifeward Ltd. (LFWD) 10 years ago, at the close on October 21, 2016, it would have been worth $5 at the close on October 21, 2026: −99.95% in total, −53.25% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −20.57% |
| 2025 | −66.65% |
| 2024 | −68.23% |
| 2023 | +2.37% |
| 2022 | −38.21% |
| 2021 | −6.82% |
| 2020 | −38.89% |
| 2019 | −50.34% |
| 2018 | −84.18% |
| 2017 | −60.71% |
| 2016 (partial year) | −56.72% |
As of October 21, 2026.
LFWD Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $22.03M | −$19.91M | −90.4% |
| 2024 | $25.66M | −$28.94M | −112.8% |
| 2023 | $13.85M | −$22.13M | −159.8% |
| 2022 | $5.51M | −$19.57M | −355.1% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $22.03M | $8.43M | −$16.89M | −$19.91M | −90.4% |
| 2024 | $25.66M | $8.22M | −$19.55M | −$28.94M | −112.8% |
| 2023 | $13.85M | $4.45M | −$23.61M | −$22.13M | −159.8% |
| 2022 | $5.51M | $1.91M | −$19.10M | −$19.57M | −355.1% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
LFWD Valuation vs Medical Devices Median
Median of 145 stocks| Metric | LFWD | Medical Devices median | vs median |
|---|---|---|---|
| P/S ratio | 0.71 | 2.53 | 0.3x the median |
| Profit margin | −141.28% | −14.78% | 126.5 pts below |
Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Lifeward’s ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study
YahooLifeward Announces Publication Of Long-Term Study On User Experience Of Its ReWalk Personal Exoskeleton In 'Spinal Cord Series And Cases'
BenzingaLifeward Informed By Rami Aviram That He Will Not Assume CFO Role; Josh Hexter To Continue As Interim Principal Financial Officer, Principal Accounting Officer
BenzingaPeer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain
YahooLifeward Announces Publication Of Researcher-Led Peer-Reviewed Study Showing Potential For Individuals With Chronic Spinal Cord Injury To Use Personal Exoskeleton To Perform Everyday Activities
BenzingaLifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
Yahoo
All 10 articles ↓Show fewer ↑
Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer
YahooLifeward Appoints Josh Hexter As Interim CEO, Succeeding Mark Grant, Effective September 1; Names Rami Aviram CFO Effective November 1
BenzingaLifeward Q2 Adj. EPS $(1.46) Misses $(1.34) Estimate, Sales $6.623M Beat $6.530M Estimate
BenzingaLifeward Launches Six-Mointh Pilot Program With Ottobock Care To Enable Greater Patient Access To Its ReWalk 7 Personal Exoskeleton
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Medical Devices Stocks
Abbott Laboratories
$173.92B
MDTMedtronic plc.
$119.00B
SYKStryker Corporation
$114.15B
BSXBoston Scientific Corporation
$64.33B
EWEdwards Lifesciences Corporation
$50.95B
GEHCGE HealthCare Technologies Inc.
$31.17B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B







